Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy

Circulation

Volumn 116, Issue 20, 2007, Pages 2298-2306

  Pawlinski, Rafal ^a   Tencati, Michael ^a   Hampton, Craig R ^b   Shishido, Tetsuro ^c   Bullard, Tara A ^c   Casey, Liam M ^c   Andrade Gordon, Patricia ^d   Kotzsch, Matthias ^e   Spring, Denise ^b   Luther, Thomas ^e   Abe, Jun Ichi ^c   Pohlman, Timothy H ^b   Verrier, Edward D ^b   Blaxall, Burns C ^c   Mackman, Nigel ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Hypertrophy; Myocardial infarction; Proteases; Receptor, PAR 1; Ventricular remodeling

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; GENE DELETION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DILATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEART VENTRICLE WALL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REPERFUSION INJURY; TISSUE FACTOR GENE;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PHENOTYPE; RECEPTOR, PAR-1; REPERFUSION INJURY; THROMBOPLASTIN; VENTRICULAR MYOSINS; VENTRICULAR REMODELING;

EID: 36048945107     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.692764     Document Type: Article

References (31)

1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
2. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687.
3. Blaxall BC, Spang R, Rockman HA, Koch WJ. Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics. 2003;15:105-114.
4. Li DY, Tao L, Liu H, Christopher TA, Lopez BL, Ma XL. Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis. 2007;11:923-930.
5. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA, Molkentin JD. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2007;109:1938-1941.
6. Erlich JH, Boyle EM Jr, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol. 2000;157:1849-1862.
7. Golino P, Ragni M, Cirillo P, D'Andrea D, Ravera A, Buono C, Corcione N, Vigorito F. Recombinant human, active site-blocked factor VII reduces infarct size and the NO-reflow phenomenon in a rabbit model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2000;278:H1507-H1516.
8. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, Castellino FJ, Groger M, Wolff K, Zacharowski K. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med. 2005;11:298-304.
9. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
10. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med. 2002;12:149-154.
11. Marinissen MJ, Servitja JM, Offermanns S, Simon MI, Gutkind JS. Thrombin protease-activated receptor-1 signals through Gq- and G13-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. J Biol Chem. 2003;278:46814-46825.
12. Darrow AL, Fung-Leung W-P, Ye RD, Santulli RJ, Cheung W-M, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76:860-866.
13. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381:516-519.
14. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, Steinberg SF. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86:1054-1061.
15. Sabri A, Short J, Guo J, Steinberg SF. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res. 2002;91:532-539.
16. Moshal KS, Tyagi N, Moss V, Henderson B, Steed M, Ovechkin A, Aru GM, Tyagi SC. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med. 2005;9:704-713.
17. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, Tyagi SC. Proteaseactivated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol. 2005;288:H2770-H2777.
18. Glembotski CC, Irons CE, Krown KA, Murray SF, Sprenkle AB, Sei CA. Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem. 1993;268:20646-20652.
19. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67:2-11.
20. Pawlinski R, Tencati M, Holscher T, Pedersen B, Voet T, Tilley RE, Marynen P, Mackman N. Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Hemost. 2007;5:1693-1700.
21. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol. 1998;275:H2300-H2307.
22. Liu L, Tsai J, Aird WC. Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor. Blood. 2000;96:1772-1781.
23. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007;4:350-358.
24. Chien KR, Olson EN. Converging pathways and principles in heart development and disease: CV@CSH. Cell. 2002;110:153-162.
25. Chien KR. Stress pathways and heart failure. Cell. 1999;98:555-558.
26. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A. 1998;95:13893-13898.
27. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;20:2757-2767.
28. Ahamed J, Niessen F, Kurokawa T, Lee YK, Bhattacharjee G, Morrissey JH, Ruf W. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood. 2007;109:5251-5259.
29. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120:303-313.
30. Andrade-Gordon P, Maryanoff B, Derian CK, Zhang HC, Addo MF, Darrow A, Eckhardt A, Hoekstra W, McComsey D, Oksenberg D, Reynolds E, Santulli RJ, Scarborough RM, Smith CE, White KB. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tetheredligand receptor. Proc Natl Acad Sci U S A. 1999;96:12257-12262.
31. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161-1165.